stockportfolio.pro
Evolent Health, Inc. (EVH)
Healthcare · Health Information Services · NYSE
Evolent Health, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $254.19M | $434.95M | $627.06M | $687.12M | $924.64M | $907.96M | $1.35B | $1.96B | $2.55B | $1.88B |
| Gross profit | — | — | — | — | — | $250.41M | $316.58M | $460.47M | $367.35M | $399.88M |
| Net income | $-159.74M | $-60.66M | $-52.66M | $-301.97M | $-334.25M | $-37.60M | $-19.16M | $-113.04M | $-61.62M | $-534.51M |
| Net margin | -62.8% | -13.9% | -8.4% | -43.9% | -36.1% | -4.1% | -1.4% | -5.8% | -2.4% | -28.5% |
Source: Evolent Health, Inc. SEC filings (10-K). 13 years of history available in the interactive view.
What growth is priced into EVH stock?
At today's market cap of $510.66M, Evolent Health, Inc. is priced for free-cash-flow growth of about 30.9% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $4.75M from the FY ending 2025-12-31). For comparison, revenue 15.2%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 13 years of Evolent Health, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track EVH in your portfolio →
Evolent Health, Inc. financial history by metric
About Evolent Health, Inc.
Evolent Health, Inc., through its subsidiary, provides specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company offers integrated value-based care platform for health plan administration and management. It also provides administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients. In addition, the company provides Machinify Auth Intelligence, an artificial intelligence tool to aid nurses and physicians in completing clinical review of prior authorization requests. Evolent Health, Inc. was founded in 2011 and is headquartered in Arlington, Virginia.
Evolent Health, Inc. — frequently asked questions
What is Evolent Health, Inc.'s revenue?
Evolent Health, Inc. (EVH) reported revenue of $1.88B for fiscal year 2025, down 26.6% from the prior year, according to its SEC filings.
Is Evolent Health, Inc. profitable?
No — EVH reported a net loss of $-534.51M in fiscal 2025.
What is EVH's P/E ratio?
Evolent Health, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Evolent Health, Inc. growing?
EVH's revenue grew at roughly 15.2% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Evolent Health, Inc. have?
As of fiscal year 2025, EVH carried roughly $970.54M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Evolent Health, Inc.'s gross margin?
EVH's gross margin was 21.3% in fiscal 2025 — gross profit of $399.88M on revenue of $1.88B.
What is Evolent Health, Inc.'s market cap?
Evolent Health, Inc. (EVH) has a market capitalization of about $510.66M, based on the latest data in our nightly-refreshed cache.
When does Evolent Health, Inc.'s fiscal year end?
EVH's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into EVH stock?
At today's market cap of $510.66M, Evolent Health, Inc. is priced for free-cash-flow growth of about 30.9% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $4.75M from the FY ending 2025-12-31). For comparison, revenue 15.2%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Evolent Health, Inc.'s official SEC filings (10-K and 10-Q), covering 13 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.